---
document_datetime: 2025-12-02 05:39:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-mylan.html
document_name: emtricitabine-tenofovir-disoproxil-mylan.html
version: success
processing_time: 0.1545971
conversion_datetime: 2025-12-24 04:54:08.507011
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Emtricitabine/Tenofovir disoproxil Mylan

[RSS](/en/individual-human-medicine.xml/66462)

##### Authorised

This medicine is authorised for use in the European Union

emtricitabine / tenofovir disoproxil Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Emtricitabine/Tenofovir disoproxil Mylan](#news-on)
- [More information on Emtricitabine/Tenofovir disoproxil Mylan](#more-information-on-emtricitabinetenofovir-disoproxil-mylan-1328)
- [Related information](#related-information-707)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77697)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Emtricitabine/Tenofovir disoproxil Mylan is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). In addition, it may be used in adolescents with HIV who are resistant to first-line treatments or who cannot take them because of side effects.

Emtricitabine/Tenofovir disoproxil Mylan is also used to help prevent sexually transmitted HIV-1 infection in adults and adolescents who are at high risk of being infected (pre-exposure prophylaxis or PrEP). It should be used in combination with safer sex practices, such as use of condoms.

Emtricitabine/Tenofovir disoproxil Mylan contains two active substances, emtricitabine and tenofovir disoproxil. It is a 'generic medicine'. This means that it contains the same active substances and works in the same way as a 'reference medicine' already authorised in the EU called Truvada.

Expand section

Collapse section

## How is Emtricitabine/Tenofovir disoproxil Mylan used?

Emtricitabine/Tenofovir disoproxil Mylan can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.

Emtricitabine/Tenofovir disoproxil Mylan is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil). The recommended dose for treating or preventing HIV-1 infection is one tablet once a day, preferably taken with food. If patients need to stop taking emtricitabine or tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.

For more information about using Emtricitabine/Tenofovir disoproxil Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Emtricitabine/Tenofovir disoproxil Mylan work?

Emtricitabine/Tenofovir disoproxil Mylan contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a 'prodrug' of tenofovir. This means that it is converted into tenofovir in the body. Tenofovir is a nucleotide reverse transcriptase inhibitor. Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected.

For the treatment of HIV-infection, Emtricitabine/Tenofovir disoproxil Mylan, taken in combination with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level. Emtricitabine/Tenofovir disoproxil Mylan does not cure HIV infection or AIDS, but it holds off damage to the immune system and the development of infections and diseases associated with AIDS.

For pre-exposure prophylaxis of HIV-1 infection, it is expected that Emtricitabine/Tenofovir disoproxil Mylan in the blood will stop the virus from multiplying and spreading from the site of infection in case the individual is exposed to the virus.

## How has Emtricitabine/Tenofovir disoproxil Mylan been studied?

Studies on the benefits and risks of the active substances in the authorised uses have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Mylan.

As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Mylan. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Emtricitabine/Tenofovir disoproxil Mylan?

Because Emtricitabine/Tenofovir disoproxil Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Emtricitabine/Tenofovir disoproxil Mylan authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Mylan has been shown to have comparable quality and to be bioequivalent to Truvada. Therefore, the Agency's view was that, as for Truvada, the benefit of Emtricitabine/Tenofovir disoproxil Mylan outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Mylan?

The company that markets Emtricitabine/Tenofovir disoproxil Mylan will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Mylan on kidney function and information about use for pre-exposure prophylaxis. Healthcare professionals will also receive a brochure and reminder card to hand out to individuals receiving the medicine for preexposure prophylaxis.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Mylan have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Mylan are continuously monitored. Side effects reported with Emtricitabine/Tenofovir disoproxil Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Emtricitabine/Tenofovir disoproxil Mylan

Emtricitabine/Tenofovir disoproxil Mylan received a marketing authorisation valid throughout the EU on 16 December 2016.

Emtricitabine / Tenofovir disoproxil Mylan : EPAR - Summary for the public

Reference Number: EMA/693101/2016

English (EN) (122.44 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 12/07/2019

[View](/en/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-95)

български (BG) (125.25 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/bg/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_bg.pdf)

español (ES) (97 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/es/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_es.pdf)

čeština (CS) (121.65 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/cs/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_cs.pdf)

dansk (DA) (95.91 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/da/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (98.09 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/de/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (95.46 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/et/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (137.11 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/el/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_el.pdf)

français (FR) (97.78 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/fr/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (117.53 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/hr/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_hr.pdf)

italiano (IT) (96.18 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/it/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (120.9 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/lv/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (119.66 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/lt/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_lt.pdf)

magyar (HU) (117.4 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/hu/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_hu.pdf)

Malti (MT) (130.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/mt/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (97.1 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/nl/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_nl.pdf)

polski (PL) (123.67 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/pl/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_pl.pdf)

português (PT) (97.07 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/pt/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_pt.pdf)

română (RO) (126.6 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/ro/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (121.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/sk/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (114.85 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/sl/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (95.97 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/fi/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_fi.pdf)

svenska (SV) (96.15 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

12/07/2019

[View](/sv/documents/overview/emtricitabine-tenofovir-disoproxil-mylan-epar-summary-public_sv.pdf)

Emtricitabine/Tenofovir disoproxil Mylan : EPAR - Risk Management Plan

English (EN) (5.69 MB - PDF)

**First published:** 15/06/2023

[View](/en/documents/rmp-summary/emtricitabinetenofovir-disoproxil-mylan-epar-risk-management-plan_en.pdf)

## Product information

Emtricitabine/Tenofovir disoproxil Mylan : EPAR - Product information

English (EN) (641.81 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 30/06/2025

[View](/en/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-609)

български (BG) (694.4 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/bg/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_bg.pdf)

español (ES) (692.55 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/es/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_es.pdf)

čeština (CS) (601.43 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/cs/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_cs.pdf)

dansk (DA) (662.36 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/da/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_da.pdf)

Deutsch (DE) (643.51 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/de/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_de.pdf)

eesti keel (ET) (476.53 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/et/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_et.pdf)

ελληνικά (EL) (476.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/el/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_el.pdf)

français (FR) (683.74 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/fr/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_fr.pdf)

hrvatski (HR) (748.19 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/hr/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_hr.pdf)

íslenska (IS) (695.78 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/is/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_is.pdf)

italiano (IT) (704.03 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/it/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_it.pdf)

latviešu valoda (LV) (647.86 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/lv/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (782.9 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/lt/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_lt.pdf)

magyar (HU) (815.58 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/hu/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_hu.pdf)

Malti (MT) (986.49 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/mt/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_mt.pdf)

Nederlands (NL) (696.52 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/nl/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_nl.pdf)

norsk (NO) (481.67 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/no/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_no.pdf)

polski (PL) (815.73 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/pl/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_pl.pdf)

português (PT) (494.39 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/pt/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_pt.pdf)

română (RO) (863.47 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/ro/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_ro.pdf)

slovenčina (SK) (478.58 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/sk/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_sk.pdf)

slovenščina (SL) (476.96 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/sl/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_sl.pdf)

Suomi (FI) (690.17 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/fi/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_fi.pdf)

svenska (SV) (695.52 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

30/06/2025

[View](/sv/documents/product-information/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000279174 27/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Emtricitabine / Tenofovir disoproxil Mylan : EPAR - All Authorised presentations

English (EN) (285.84 KB - PDF)

**First published:** 03/02/2017

**Last updated:** 05/12/2023

[View](/en/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-960)

български (BG) (140.66 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/bg/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (53.48 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/es/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.06 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/cs/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.68 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/da/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (31.06 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/de/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (51.64 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/et/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.85 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/el/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (22.2 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/fr/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (74.74 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/hr/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.69 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/is/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.99 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/it/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.54 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/lv/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (96.82 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/lt/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (72.27 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/hu/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.3 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/mt/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.88 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/nl/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.72 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/no/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.73 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/pl/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.39 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/pt/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.79 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/ro/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.11 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/sk/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (88.26 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/sl/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (73.65 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/fi/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.82 KB - PDF)

**First published:**

03/02/2017

**Last updated:**

05/12/2023

[View](/sv/documents/all-authorised-presentations/emtricitabine-tenofovir-disoproxil-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Emtricitabine/Tenofovir disoproxil Mylan Active substance

- emtricitabine
- tenofovir disoproxil maleate

International non-proprietary name (INN) or common name

- emtricitabine
- tenofovir disoproxil

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

**Treatment of HIV-1 infection:**

- Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1).
- Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1).

**Pre-exposure prophylaxis (PrEP):**

- Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).

## Authorisation details

EMA product number EMEA/H/C/004050

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park

Opinion adopted 13/10/2016 Marketing authorisation issued 16/12/2016 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Emtricitabine/Tenofovir disoproxil Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (476.54 KB - PDF)

**First published:** 12/07/2024

**Last updated:** 30/06/2025

[View](/en/documents/procedural-steps-after/emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Emtricitabine/Tenofovir disoproxil Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (140.96 KB - PDF)

**First published:** 27/06/2017

**Last updated:** 05/12/2023

[View](/en/documents/procedural-steps-after/emtricitabine-tenofovir-disoproxil-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Emtricitabine / Tenofovir disoproxil Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/636453/2016

English (EN) (1.04 MB - PDF)

**First published:** 03/02/2017

**Last updated:** 03/02/2017

[View](/en/documents/assessment-report/emtricitabine-tenofovir-disoproxil-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Emtricitabine/Tenofovir disoproxil Mylan

Adopted

Reference Number: EMA/CHMP/659472/2016

English (EN) (118.87 KB - PDF)

**First published:** 14/10/2016

**Last updated:** 14/10/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabinetenofovir-disoproxil-mylan_en.pdf)

#### News on Emtricitabine/Tenofovir disoproxil Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2016) 14/10/2016

#### More information on Emtricitabine/Tenofovir disoproxil Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0040500000) (initial marketing authorisation)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Emtricitabine/Tenofovir disoproxil Mylan : EPAR - Product information - tracked changes

English (EN) (194.01 KB - DOCX)

**First published:** 30/06/2025

[View](/en/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-712)

български (BG) (185.04 KB - DOCX)

**First published:**

30/06/2025

[View](/bg/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_bg.docx)

español (ES) (167.44 KB - DOCX)

**First published:**

30/06/2025

[View](/es/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_es.docx)

čeština (CS) (182.19 KB - DOCX)

**First published:**

30/06/2025

[View](/cs/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (162.05 KB - DOCX)

**First published:**

30/06/2025

[View](/da/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (172.98 KB - DOCX)

**First published:**

30/06/2025

[View](/de/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (157.95 KB - DOCX)

**First published:**

30/06/2025

[View](/et/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (177.41 KB - DOCX)

**First published:**

30/06/2025

[View](/el/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_el.docx)

français (FR) (179.04 KB - DOCX)

**First published:**

30/06/2025

[View](/fr/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (149.25 KB - DOCX)

**First published:**

30/06/2025

[View](/hr/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (165.54 KB - DOCX)

**First published:**

30/06/2025

[View](/is/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_is.docx)

italiano (IT) (152.05 KB - DOCX)

**First published:**

30/06/2025

[View](/it/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (168.81 KB - DOCX)

**First published:**

30/06/2025

[View](/lv/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (143.78 KB - DOCX)

**First published:**

30/06/2025

[View](/lt/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (171.62 KB - DOCX)

**First published:**

30/06/2025

[View](/hu/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (164.92 KB - DOCX)

**First published:**

30/06/2025

[View](/mt/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (160.54 KB - DOCX)

**First published:**

30/06/2025

[View](/nl/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (170.91 KB - DOCX)

**First published:**

30/06/2025

[View](/no/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_no.docx)

polski (PL) (197.14 KB - DOCX)

**First published:**

30/06/2025

[View](/pl/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_pl.docx)

português (PT) (154.1 KB - DOCX)

**First published:**

30/06/2025

[View](/pt/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_pt.docx)

română (RO) (180.8 KB - DOCX)

**First published:**

30/06/2025

[View](/ro/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (186.39 KB - DOCX)

**First published:**

30/06/2025

[View](/sk/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (178.78 KB - DOCX)

**First published:**

30/06/2025

[View](/sl/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (176.75 KB - DOCX)

**First published:**

30/06/2025

[View](/fi/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (172.49 KB - DOCX)

**First published:**

30/06/2025

[View](/sv/documents/product-information-tracked-changes/emtricitabine-tenofovir-disoproxil-mylan-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 30/06/2025

## Share this page

[Back to top](#main-content)